Episode 44: BioNTech

Before the world knew the power of mRNA vaccines, BioNTech was a relatively quiet biotech company focused on one ambitious goal: curing cancer through the immune system. Then the COVID-19 pandemic changed everything.

In this episode of Petri Dish Perspectives: Biotech Unleashed, we explore how BioNTech evolved from an academic vision into one of the most important biotechnology companies of the 21st century. We break down the scientific bet on mRNA, the early years building a platform many investors didn’t fully understand, and the pivotal partnership with Pfizer that helped deliver one of the fastest vaccine developments in history.

But the story doesn’t stop with COVID. We also examine the criticisms, the people behind the company’s rise, and the next frontier BioNTech is chasing — personalized cancer vaccines and the future of programmable medicine.

If you want to understand how a biotech platform can reshape global health and what comes after a once-in-a-generation breakthrough, this episode is for you.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

https://linktr.ee/maneadkhin

#Biotech #BioNTech #mRNA #Biotechnology #Pharma #DrugDevelopment #COVID19 #Vaccines #BiotechPodcast #LifeSciences #HealthcareInnovation #PetriDishPerspectives

Transcript

Hello and welcome to Petri Dish Perspectives, the podcast where we geek out about science and the companies shaping the future of healthcare. I’m your host, Manead, and I’m a PhD scientist by training, biotech storyteller by choice. With every new episode released on Thursday, my goal is to deliver digestible pieces of information on healthcare companies under 30 mins. 

Today we’re diving into one of the most fascinating biotech stories of the modern era: BioNTech.

Now, depending on who you ask, BioNTech is either:

• the company that helped save millions of lives during the COVID-19 pandemic,
• a symbol of the speed of modern biotechnology,
• or a controversial example of how science, government funding, and global access intersect during a crisis.

But here’s the deeper truth: BioNTech was never originally built to fight pandemics.

It was built to cure cancer.

And the technology behind its success — messenger RNA, or mRNA — had been quietly developing for decades before the world suddenly needed it.

Today, we’ll break down:

• How BioNTech started,
• Why investors initially doubted mRNA.
• The moment the company pivoted to COVID,
• The partnership that changed everything,
• And what BioNTech is trying to become in the post-pandemic world.

Because the real story of BioNTech isn’t just about vaccines.

It’s about platform biotechnology.

Quick disclaimer, I give full credit to the original articles cited in the references in the transcript!

Grab a coffee or tea, settle in, and let’s jump in!

Establishment — The Scientific Vision

BioNTech was founded in 2008 in Mainz, Germany.

The founders were a husband-and-wife team of physician-scientists:

• Uğur Şahin
• Özlem Türeci

The "Dream Team" of biotechnology, Uğur Şahin and Özlem Türeci, are Turkish-German physician-entrepreneurs whose shared obsession with the immune system redefined modern medicine. Born to immigrant families—Şahin the son of a Ford factory worker and Türeci the daughter of a surgeon—the couple famously spent their 2002 wedding day returning to the lab to finish experiments, a testament to the work ethic that would eventually yield the world’s first mRNA vaccine. After selling their first firm, Ganymed, for $1.4 billion, they founded BioNTech in 2008 to pursue "individualized" cancer therapies, a platform they pivoted overnight in early 2020 to launch Project Lightspeed. Today, despite their multi-billion-dollar success and Nobel-caliber impact, they remain famously modest, commuting by bicycle and focusing their post-pandemic momentum on their original mission: teaching the body to "print" its own cure for cancer.

Both were deeply immersed in cancer immunology.

Their core idea was radical but elegant:

Instead of developing one drug at a time, build a platform that teaches the immune system to recognize disease.

And mRNA was the key.

The concept is simple but powerful.

Messenger RNA acts like a biological instruction manual. Instead of injecting a protein drug, you deliver instructions that tell the body to produce the therapeutic target itself.

At the time, this approach had major skepticism.

mRNA was considered unstable.
 Manufacturing was difficult.
 And delivery systems were still experimental.

But Sahin believed something important:

Cancer is fundamentally a genetic disease.

If you can read the mutations in a tumor and design an mRNA therapy that trains the immune system to attack those mutations, you could create personalized cancer vaccines.

This became BioNTech’s founding thesis.

And early on, the company built a deep technology stack around:

• mRNA therapeutics
• individualized neoantigen cancer vaccines
• cell therapies
• antibody engineering
• AI-driven antigen discovery

But there was a problem.

The world didn’t yet believe in mRNA.

The Long Road Before the Spotlight

For more than a decade, BioNTech operated largely under the radar.

Unlike many biotech startups that chase quick IPOs, BioNTech focused on building infrastructure.

They invested heavily in:

• manufacturing
• bioinformatics
• translational immunology
• clinical oncology programs

And they partnered early with big pharma.

One of the most important early partnerships was with Genentech, part of Roche, to develop cancer immunotherapies.

These collaborations validated BioNTech’s science but also revealed a key challenge:

mRNA therapeutics required large-scale manufacturing expertise that most biotech startups didn’t yet have.

So BioNTech quietly built it.

And that decision would later become critical.

Rise to Fame — IPO and Platform Validation

BioNTech eventually went public in 2019 on the NASDAQ.

The IPO raised roughly $150 million. BioNTech (NASDAQ: BNTX) launched its IPO on October 10, 2019, selling 10 million American Depositary Shares (ADS) at $15 per share, valuing the company at approximately $3.39 billion. 

Notably, the offering happened during a period when investors were still uncertain about mRNA technology.

Another company in the same space, Moderna, had already gone public the year before — but the entire mRNA field was still seen as experimental.

At the time of the IPO, BioNTech was still positioned primarily as an oncology company.

Most of its pipeline was focused on:

• melanoma
• solid tumors
• individualized cancer vaccines
• T cell therapies

Few people expected what would happen just months later.

Because in late 2019, the world changed.

The COVID-19 Pivot

In January 2020, reports of a novel coronavirus began emerging.

Uğur Şahin reportedly read a scientific paper describing the virus and immediately recognized the potential risk of a global pandemic.

Within days, BioNTech initiated what they internally called Project Lightspeed.

The goal:

Design an mRNA vaccine against SARS-CoV-2 as quickly as possible.

This was an enormous gamble.

At that time:

• No mRNA vaccine had ever been approved.
• Global manufacturing infrastructure didn’t exist.
• Clinical trials needed to move at unprecedented speed.

But BioNTech had one advantage:

Their platform was built exactly for rapid design.

mRNA sequences can be generated quickly once the viral genome is known.

Within weeks, BioNTech had multiple vaccine candidates.

However, they needed global scale.

And that’s where a critical partnership came in.

The Pfizer Collaboration That Changed Everything

In 2018, Pfizer and BioNTech signed a partnership to develop mRNA-based influenza vaccines.

At the time:

• BioNTech had advanced mRNA platform technology
• Pfizer had deep experience in vaccines, clinical trials, and global distribution

The deal structure was typical for biotech–pharma collaborations:

• Pfizer paid BioNTech upfront funding
• Pfizer supported development and commercialization
• BioNTech provided the mRNA technology platform

This partnership created:

• established scientific collaboration
• legal agreements already in place
• operational communication channels between the companies

That pre-existing relationship is the key reason things moved extremely fast later.

BioNTech partnered with Pfizer.

This collaboration became one of the most important biotech partnerships in modern history.

Here’s why it worked so well:

BioNTech brought:

• mRNA platform technology
• vaccine design
• immunology expertise

Pfizer brought:

• global clinical trial execution
• manufacturing scale
• regulatory infrastructure
• worldwide distribution networks
  
  
  

Together, they developed the vaccine known as BNT162b2 — later marketed as Comirnaty.

In December 2020, the vaccine received emergency authorization in multiple countries, including the United States.

It became the first widely deployed mRNA vaccine in history.

And the results were remarkable.

Clinical trials showed efficacy around 95% against symptomatic COVID-19 infection early in the pandemic.

Within a year:

BioNTech went from a relatively niche biotech company to a global household name.

Revenue surged dramatically.

At one point, the vaccine generated tens of billions of dollars in annual revenue.

This transformed BioNTech’s balance sheet overnight.

Criticism and Controversies

But with massive success came scrutiny.

BioNTech and Pfizer faced several major criticisms during the pandemic.

One of the biggest was vaccine equity.

Many lower-income countries struggled to access doses early in the rollout.

Critics argued that pharmaceutical companies prioritized wealthier nations.

Another issue was intellectual property debates.

There were calls to waive patents to allow broader global vaccine manufacturing.

This sparked intense debate about the balance between:

• innovation incentives
• public health access
• and global crisis response.

There were also controversies related to:

rapid vaccine development timelines,
 misinformation around mRNA technology,
 and evolving guidance around boosters.

Despite this, real-world data consistently showed the vaccines saved millions of lives globally.

From a biotech industry perspective, the success of mRNA changed the perception of the entire modality.

It validated decades of research that had previously struggled for mainstream acceptance.

People Who Made Their Mark

Several individuals played pivotal roles in the BioNTech story.

First, of course, Uğur Şahin.

He is widely considered one of the most visionary scientists in modern biotech.

His long-term commitment to mRNA — even when the field was uncertain — is a major reason BioNTech was prepared when the pandemic hit.

Next, Özlem Türeci.

She has been central to the scientific leadership of the company, particularly in immunology and translational medicine.

Together, they built a company culture heavily focused on science-first decision making.

Another key figure is Albert Bourla, the CEO of Pfizer, who pushed aggressively to accelerate vaccine development timelines during the pandemic.

And across both organizations, thousands of scientists, clinicians, regulatory experts, and manufacturing teams worked at unprecedented speed.

This is one of those rare biotech stories where execution across multiple organizations was nearly flawless.

Lessons From BioNTech

There are several strategic lessons from BioNTech’s journey.

Lesson 1: Platform technologies can change the rules of biotech.

Traditional pharma develops drugs one-by-one.

BioNTech built a system capable of generating many therapies rapidly.

This dramatically shortens development cycles.

Lesson 2: Scientific conviction matters.

mRNA was considered risky for years.

But long-term investment in a breakthrough modality can pay off — if the science is sound.

Lesson 3: Manufacturing is strategy.

Many biotech companies underestimate manufacturing.

BioNTech invested early in scalable production.

That decision enabled them to respond rapidly to COVID.

Lesson 4: Partnerships can multiply impact.

Without Pfizer, BioNTech likely couldn’t have scaled globally as quickly.

The partnership model between biotech innovation and pharma infrastructure proved extremely effective.

What’s Next for BioNTech

Now that COVID vaccine demand has stabilized, BioNTech is entering a new phase.

The company is reinvesting pandemic revenue into its original mission: cancer immunotherapy.

Major focus areas include:

mRNA cancer vaccines
 neoantigen-based personalized therapies
 combination immunotherapies
 and next-generation infectious disease vaccines.

BioNTech is also working on oncology collaborations with Genentech and exploring new partnerships globally.

One of the most closely watched programs is their individualized cancer vaccine platform — designed to create patient-specific treatments based on tumor sequencing.

If this works at scale, it could redefine oncology treatment.

Additionally, BioNTech is investing in:

• AI-driven drug discovery
• new manufacturing facilities
• infectious disease pipelines beyond COVID
• malaria and tuberculosis vaccine research
  
  
  

In many ways, BioNTech is trying to transition from a pandemic hero into a long-term platform biotech company.

And that transformation is not guaranteed.

History shows that many companies struggle after a single blockbuster product.

But BioNTech has something many of those companies did not:

massive capital, validated technology, and a clear scientific roadmap.

Outro

The story of BioNTech is ultimately a story about preparation meeting opportunity.

For more than a decade, the company built technology that the world didn’t yet need.

Until suddenly, it did.

And when the moment came, BioNTech was ready.

That’s a powerful lesson in biotechnology — because in this industry, breakthroughs often look like overnight successes.

But in reality, they’re built on decades of work.

If you enjoyed this episode of Petri Dish Perspectives, be sure to follow and share. 

This has been Petri Dish Perspectives. I’m Manead. Thanks for listening. See you next Thursday. Good bye.

References

1. www.wikipedia.org
2. https://www.biontech.com/int/en/home.html 
3. https://www.fiercebiotech.com/ 
4. https://finance.yahoo.com/ 
5. https://www.forbes.com/sites/giacomotognini/2025/09/29/tanking-covid-19-vaccine-sales-are-crushing-biotech-billionaire-fortunes/